Report of Foreign Issuer (6-k)
April 03 2018 - 8:33AM
Edgar (US Regulatory)
UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE
13a-16
OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of April 2018
Commission File Number:
001-36697
DBV TECHNOLOGIES S.A.
(Translation of registrant’s name into English)
177-181
avenue Pierre Brossolette
92120 Montrouge France
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form
20-F
or Form
40-F:
☒ Form
20-F ☐ Form
40-F
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(7): ☐
EXHIBIT LIST
|
|
|
|
|
Exhibit
|
|
Description
|
|
|
|
|
99.1
|
|
Press Release dated April 3, 2018.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DBV TECHNOLOGIES S.A.
|
|
|
|
|
|
|
Date: April 3, 2018
|
|
|
|
By:
|
|
/s/ David Schilansky
|
|
|
|
|
|
|
|
Name:
|
|
David Schilansky
|
|
|
|
|
|
|
|
Title:
|
|
Deputy Chief Executive Officer
|
Exhibit 99.1
|
|
|
|
|
|
Montrouge, April 3, 2018
|
DBV Technologies to Attend the 11
th
Kempen Life Sciences Conference
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced that Susanna Mesa, Chief Business Officer, will
host investor meetings during the 11
th
Kempen Life Sciences Conference on Wednesday, April 18, 2018 at the Kempen & Co offices in Amsterdam, Netherlands.
About DBV Technologies
DBV Technologies is developing
Viaskin
®
, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT
®
, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and
non-invasive
product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include
ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human
proof-of-concept
clinical study of
Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares
are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing
one-half
of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website:
www.dbv-technologies.com
DBV Investor Relations Contact
Sara Blum Sherman
Senior Director, Investor Relations & Strategy
+1 212-271-0740
sara.sherman@dbv-technologies.com
DBV Media Contact
Roberta Di Giorgio
Senior Director, Corporate Communications
+1 917-612-2861
roberta.digiorgio@dbv-technologies.com
DBV Technologies (NASDAQ:DBVT)
Historical Stock Chart
From Aug 2024 to Sep 2024
DBV Technologies (NASDAQ:DBVT)
Historical Stock Chart
From Sep 2023 to Sep 2024
